On Thursday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: EZCORP, Inc. (NASDAQ:EZPW), Amarin Corporation plc (NASDAQ:AMRN), CTI BioPharma Corp. (NASDAQ:CTIC), Sanofi (NYSE:SNY)
EZCORP, Inc. (NASDAQ:EZPW), with shares declined -5.87%, closed at $9.46.
Amarin Corporation plc (NASDAQ:AMRN), with shares dropped -5.83%, settled at $2.26.
CTI BioPharma Corp. (NASDAQ:CTIC), with shares dipped -5.76%, and closed at $1.80, hitting new 52-week low of $1.77.
Sanofi (NYSE:SNY), plummeted -2.98%, and closed at $48.80.
Latest NEWS regarding these Stocks are depicted underneath:
EZCORP, Inc. (NASDAQ:EZPW)
Formerly on March 2, EZCORP, Inc. (EZPW), declared that Mark Ashby has been designated Chief Financial Officer. In that role, Mr. Ashby will be responsible for EZCORP’s accounting, financial planning and analysis, internal audit, investor relations, tax, and treasury functions.
Mr. Ashby has more than 30 years of finance and business experience, serving in a variety of senior financial administration and operational roles. Mr. Ashby joins EZCORP from Myer Holdings Limited, Australia’s largest department store group, where he served as Chief Financial Officer for seven years. Myer Holdings recorded sales of over $3.1 billion (AUS) in its most recent fiscal year and operates 67 stores across Australia supported by online, digital and mobile platforms. Mr. Ashby joined Myer in January 2008 and was instrumental in the turnaround of the corporation and its subsequent successful IPO in 2009.
Mr. Ashby received a Bachelor of Business, Accounting from Swinburne University, and is a Fellow of the Australian Society of Certified Practicing Accountants.
EZCORP, Inc. provides specialty consumer financial services. The corporation operates in three segments: The U.S. & Canada, Latin America, and Other International. The corporation offers pawn loans, which are non-recourse loans collateralized by tangible personal property, counting jewelry, consumer electronics, tools, sporting goods, and musical instruments; sells merchandise comprising of second-hand collateral forfeited from its pawn lending activities or purchased from customers, and new or refurbished merchandise from third party vendors; and buys and sells second-hand goods.
Amarin Corporation plc (NASDAQ:AMRN)
Formerly on March 16, Amarin Corporation plc (AMRN), declared the presentation of findings from a new in vitro study showing that pretreatment with eicosapentaenoic acid (EPA), an omega-3 fatty acid, reduced oxidation of small dense LDL (sdLDL) and resulted in improved endothelial function when contrast to other triglyceride (TG)-lowering agents, counting fenofibrates, niacin and gemfibrozil. The research was presented recently at a peer-reviewed poster session at the American College of Cardiology Scientific Session in San Diego, California.
Researchers found that EPA pretreatment protected sdLDL particles from oxidative damage, reducing sdLDL oxidation by >90% (p<0.001) as contrast with the absence of EPA treatment. When applied directly to human umbilical vein endothelial cells (HUVECs), the vehicle-treated oxidized sdLDL significantly reduced NO release by 20% as contrast with non-oxidized sdLDL. Following exposure to sdLDL that had been treated with EPA preceding to oxidation, however, HUVEC release of NO raised significantly by 53% and 23%, as contrast with treatment with oxidized sdLDL and non-oxidized sdLDL treatments, respectively. All of the other TG-lowering agents failed to inhibit sdLDL oxidation, and instead resulted in noteworthy reductions in NO release contrast to vehicle-treated oxidized sdLDL.
The study was supported by Amarin and led by a researcher at Brigham and Women’s Hospital in partnership with investigators at Elucida Research in Beverly, Massachusetts and Ohio University in Athens, Ohio.
Amarin Corporation plc, a biopharmaceutical corporation, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The corporation’s lead product comprises Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
CTI BioPharma Corp. (NASDAQ:CTIC)
Formerly on March 16, CTI BioPharma Corp. (CTIC), declared that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor presently in Phase 3 development in the PERSIST program. Dr. Rami S. Komrokji, Associate Professor of Oncologic Sciences at the University of South Florida College of Medicine and Clinical Director of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla., was the lead author.
Results of the Phase 2 study demonstrated that pacritinib is active in patients with myelofibrosis, resulting in spleen volume reduction, while producing substantial and prolonged improvement in disease-related symptoms without causing clinically noteworthy myelosuppression. We believe pacritinib was well tolerated, counting in patients with disease-related anemia and thrombocytopenia, with the predominant side effect being manageable gastrointestinal toxicity.
CTI BioPharma Corp., a biopharmaceutical corporation, engages in the attainment, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union.
Sanofi (NYSE:SNY)
Genzyme, a Sanofi (SNY), declared that the sixth annual Gaucher Leadership Forum (GLF) will take place on March 27 and 28 in Berlin, Germany.
The GLF is a scientific meeting sponsored by Genzyme that brings together about 200 participants from around the world, counting physicians, academics, researchers and patient organization representatives to talk about current care for patients with Gaucher disease and the direction of future disease administration. This year’s GLF will be chaired by Timothy M. Cox, Professor of Medicine at the University of Cambridge. The theme for 2015 is: “New Clinical Science of Gaucher Disease” and will focus on the following objectives:
- Advancing therapeutics through greater understanding of pathogenesis (molecular & otherwise).
- Fostering collaborative and interdisciplinary research.
- Inspiring (recruiting) the next generation of clinician researchers and scientists.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
